ACE and chronic kidney disease: The proportion of prevalent CKD patients who had dual prescriptions of ACE inhibitors and ARBs (QIACEi+ARB) was 4.2% (95% CI 3.8; 4.7) in 2012 and declined to 1.3% (95% CI 1.2; 1.6) in 2018.